The Medicare GLP-1 Bridge is a temporary CMS program that gives eligible Medicare Part D beneficiaries access to certain GLP-1 medications for weight management for a $50 monthly copayment. The program runs from July 1, 2026, through December 31, 2027
The program is available nationwide, but not everyone with Medicare qualifies. Eligibility depends on your Medicare drug coverage, health conditions, and other requirements
Medicare GLP-1 Bridge at a Glance
| Question | Answer |
|---|---|
| What is it? | A temporary CMS program providing eligible Medicare beneficiaries access to certain GLP-1 medications for weight management |
| When does it run? | July 1, 2026 – December 31, 2027 |
| How much does it cost? | $50 copay for a one-month supply |
| Who can qualify? | Eligible Medicare Part D beneficiaries who meet the program’s requirements |
| Which medications are included? | Foundayo, Wegovy, and Zepbound KwikPen |
| Does the $50 count toward my Part D deductible? | No |
| Where can I learn more? | Medicare.gov/glp1bridge or by calling 1-800-MEDICARE |
What are GLP-1 medications?
GLP-1 medications, or glucagon-like peptide-1 receptor agonists, were originally developed to help patients manage Type 2 diabetes. Over time, researchers discovered these medicines could also help regulate appetite, reduce cravings, slow digestion, and support significant weight loss, and improve health outcomes
Today, these medications, such as Wegovy, Ozempic, and Zepbound, have become central to modern obesity treatment and are common household names. Clinical studies show that many patients lose substantial amounts of body weight while taking these medications and following important steps to stay physically active, eat right, and get enough sleep
For those who live with obesity, weight reduction can improve mobility, decrease joint pain, lower blood pressure, improve blood sugar control, and reduce cardiovascular risk. Some evidence also suggests GLP-1 medications may help lower the risk of heart attacks and strokes in certain patients with obesity and heart disease
But access has remained difficult because of cost
How does the Medicare GLP-1 Bridge program work?
The program creates a pathway for eligible Medicare beneficiaries to access GLP-1 medications at reduced costs while federal officials continue evaluating broader coverage policies
- Participating manufacturers will provide GLP-1 medications at a reduced net price of approximately $245 per month.
- Eligible beneficiaries pay $50 for a one-month supply of a covered GLP-1 medication through the Medicare GLP-1 Bridge. The $50 copay is separate from regular Medicare Part D coverage, so it does not count toward the Part D deductible or yearly out-of-pocket limit. It also cannot be reduced through Extra Help.
| The $50 copay is the cost for the eligible medication under the Bridge. It does not mean a person’s total Medicare health care costs will be $50 per month. |
This is a meaningful reduction compared to current retail prices and makes a big difference to older adults living on a fixed income
Officials with the Centers for Medicare and Medcaid Services (CMS) are calling the program a “bridge” to the BALANCE Model, which stands for Better Approaches to Lifestyle and Nutrition for hEalth.
“As part of this voluntary model, CMS will negotiate drug pricing and coverage terms with manufacturers of GLP-1 medications on behalf of state Medicaid agencies and Medicare Part D plan sponsors,” according to a CMS webpage
Who is eligible for the Medicare GLP-1 Bridge program?
Not every Medicare beneficiary will automatically qualify for the Bridge program. Eligibility depends on medical necessity and provider documentation. Medicare coverage rules can be complex, and many people don’t learn about new benefits unless they come up during a doctor’s visit or a Medicare counseling session
If you think you may qualify, don’t assume you aren’t—or that you’ll automatically be enrolled. Talk with your health care provider, and review your Medicare Part D prescription drug coverage, before starting treatment. Health care providers must verify that patients have obesity along with qualifying health conditions that may include:
- Heart failure
- Prediabetes
- Cardiovascular disease
- Type 2 diabetes
- Hypertension
- Sleep apnea
Patients will likely need ongoing medical supervision while taking these medications. Providers may monitor:
- Weight changes
- Blood sugar levels
- Cardiovascular health
- Kidney function
- Medication side effects
This oversight underscores the importance that obesity treatment should involve comprehensive medical care rather than simply prescribing medication alone
What are the criteria for accessing the Medicare GLP-1 Bridge?
Under the new program, health care providers may prescribe GLP-1 drugs for obesity so long as patients meet eligibility requirements, such as:
- A body mass index (BMI) of 35 or higher
- A BMI of 30 or higher as well as diagnosed heart failure, uncontrolled hypertension, or kidney disease
- A BMI of 27 or higher as well as previous stroke, prediabetes, a previous heart attack, or peripheral artery disease
The Medicare GLP-1 Bridge is different from regular Medicare Part D drug coverage. Patients must be enrolled in a Medicare Part D or Medicare Advantage plan to access the temporary GLP-1 benefit. And a doctor must submit a prior authorization request to a central processing center, confirming the patient has received counseling on lifestyle changes while taking GLP-1 drugs. Patients can fill their prescription once the request is approved and the pharmacy is notified
What should I do if I think I qualify for the Medicare GLP-1 Bridge program?
If you think you may qualify for the Medicare GLP-1 Bridge, there are several steps you can take to find out if the program is right for you and begin the enrollment process. Start by talking with your health care provider and use the steps below to understand your eligibility, prior authorization requirements, and next steps
Steps to Take If You Think You Qualify
| 1.Talk with your health care provider. |
| 2. Ask whether you meet the Bridge’s eligibility requirements. |
| 3. Ask your provider to submit the required prior authorization. |
| 4. Confirm that the prescribed medication is one of the medications covered through the Bridge. |
| 5. Visit Medicare.gov/glp1bridge or call 1-800-MEDICARE with questions. |
What are the risks of GLP-1 medications for older adults?
Older adults may face concerns because rapid weight loss can sometimes contribute to muscle loss, weakness, or nutritional deficiencies if not carefully managed
Patients with certain conditions, including severe gastrointestinal disorders, pancreatitis history, or kidney disease, may require additional evaluation before starting treatment
Experts recommend combining medication use with:
- Balanced nutrition
- Adequate protein intake
- Strength-building exercise
- Regular medical monitoring
This is especially important for older adults seeking to preserve muscle mass and physical independence while losing weight
Which GLP-1 medications are covered by the Medicare GLP-1 Bridge?
The Bridge program won’t include all GLP-1 drugs Only Foundayo (a new GLP-1 pill from Eli Lilly), Wegovy (both injectables and oral pills), and the Zepbound KwikPen will be covered
What older adults should do now
Beneficiaries can begin by discussing obesity treatment options with their health care providers
Important questions to ask include:
- Do I meet likely eligibility requirements?
- Which GLP-1 medication may be appropriate for me?
- What side effects should I expect?
- How will treatment affect my other medications?
- What costs will I be responsible for?
- Will I need ongoing monitoring or nutrition counseling?
For older adults, however, the message is becoming clearer: obesity treatment is entering a new era. The GLP-1 Bridge program may not solve every challenge. But it represents an important step toward expanding access to potentially life-changing therapies for millions of Medicare beneficiaries
Interested in learning more about the new Medicare GLP-1 Bridge program? Register for this webinar featuring an overview of the program and an opportunity to ask questions about eligibility, prior authorization, and next steps.
Sources
1. Obesity Action Coalition. Changes are Coming: Medicare Accewss to GLP-1 Medications. April 24, 2026. Found on the internet at https://www.obesityaction.org/changes-are-coming-medicare-access-to-glp-1-medications/
2. National Community Pharmacists Association. CMS kicks the can on weight loss GLP-1 drugs. April 23, 2026. Found on the internet at https://ncpa.org/newsroom/qam/2026/04/23/cms-kicks-can-weight-loss-glp-1-drugs
3. Centers for Medicare and Medicaid Services (CMS). Frequently Asked Questions Related to the Medicare GLP-1 Bridge. March 3, 2026. Found on the internet at https://www.reedsmith.com/media/l3inc0ds/medicare-glp-1-bridge-faqs.pdf
4. Meredith Freed, Juliette Kubanski, and Elizabeth Williams. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. May 11, 2026. KFF. Found on the internet at https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
5. CMS. BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. Found on the internet at https://www.cms.gov/priorities/innovation/innovation-models/balance
